you are viewing a single comment's thread.
I suspect you may be trolling, but in case you are serious, Genzyme sells over $1bn worth of Cerezyme a year for a disease that is about as rare. It charges $200k - $300k per patient, per year. http://www.genzyme.com/commitment/patients/costof_treatment.aspBiomarin has similar drugs for related diseases, and charges about the same. Perhaps you should do a bit of reading before more posting.Good luck.
Thanks Fatty, I'll take yout word for it and hang on for more profit.At one time Trimeris had a big fish on the line but let it get away.Synageva just seems to be trying to hook little fish.That hedge fund interest is a positive sign too, long as they don't pump and dump.